TALPHERA INC (TLPH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$1.22+2.52%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Talphera aims to keep costs near $17.5 million in 2026. It has a strong pipeline in rare diseases and cancer. Recent earnings beats show some progress. The stock rose 63% in 63 days with no stress.
The company is still losing money with negative EPS. Revenue is very low and growth is uncertain. It faces Nasdaq delisting risks and needs more capital.
The market values Talphera at about $0.16 per share with high optionality. It expects very high growth but no profits soon. Our view is cautious on near-term losses and cost control.
Breaks if: EPS falls below -$0.26 in FY26
Breaks if: Operating expenses exceed $18M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces high risks, but it operates in a sector with favorable momentum that could support its recovery over the multi-year horizon.
The market appears to factor in a fragile valuation, as TLPH is priced at a significant premium compared to peers. This suggests that investors may have high expectations for future performance, despite the company's recent weak financial results.
Management is on track with key priorities, such as completing a clinical study and addressing operating expenses, though results are mixed. Recent earnings beats indicate some positive momentum, but overall financial performance remains below industry standards.
The long-term thesis hinges on management's ability to maintain progress on clinical studies and control expenses. Additionally, external factors like sector performance and economic conditions will significantly impact TLPH's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. Additionally, the completion of NEPHRO CRRT clinical study enrollment in 2026 is promising. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage cash operating expenses, including SG&A and R&D excluding stock-based compensation, to stay within $17 million to $18 million for fiscal year 2026.
Stated as a priority in 3 of last 3 quarters. Quarterly combined R&D and SG&A expenses were steady at $3.9 million in both 2026-Q1 and 2026-Q2. The 2026 full-year guidance targets cash operating expenses between $17 million and $18 million. The trajectory is stagnant with expenses stable but not yet reduced.
“Combined R&D and SG&A expenses for Q2 2026 totaled $3.9 million, excluding stock-based compensation $3.7 million.”
“Combined R&D and SG&A expenses for Q1 2026 totaled $3.9 million, excluding stock-based compensation $3.7 million.”
“Cash operating expenses expected to be in the range of $17 million to $18 million in 2026.”
Breaks if: Revenue fails to exceed $0.2 million in FY27
In the next 1 to 3 years, TLPH's prospects will depend on execution and sector dynamics. Not investment advice.